Research and Markets: Inflammatory Bowel Disease - Pipeline Review, H2 2012 Out Now

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/lr485d/inflammatory) has announced the addition of Global Markets Direct's new report "Inflammatory Bowel Disease - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Inflammatory Bowel Disease - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Inflammatory Bowel Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Inflammatory Bowel Disease.

- A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Inflammatory Bowel Disease pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Companies Mentioned:

Alcon, Inc.

Bristol-Myers Squibb Company

Baxter International Inc.

Johnson & Johnson

Abbott Laboratories

Osiris Therapeutics, Inc.

Sequella, Inc.

Amgen Inc.

Sanofi-Aventis

AstraZeneca PLC

Athersys, Inc.

Celltrion, Inc.

Sylentis

TiGenix NV

Axcan Pharma Inc.

Cephalon, Inc.

Eisai Co., Ltd.

MDRNA, Inc.

Norgine Limited

Pfizer Inc.

NPS Pharmaceuticals, Inc.

Compugen Ltd.

Ore Pharmaceuticals Inc

Cosmo Pharmaceuticals S.p.A

KOLON LIFE SCIENCE INC.

Soligenix, Inc.

ProMetic Life Sciences Inc.

Phytopharm Plc

Antisoma plc

Pluristem Therapeutics Inc.

Galapagos NV

Atlantic Pharmaceuticals, Inc.

Avaxia Biologics, Inc.

Xencor, Inc.

Trillium Therapeutics Inc.

Pepscan Therapeutics

Receptos, Inc.

N30 Pharmaceuticals

Applied Protein Sciences, LLC

AUS Bio Limited

FunZyme BioTechnologies S.A.

Immune Technologies and Medicine

Clarassance, Inc.

Advancell

For more information visit http://www.researchandmarkets.com/research/lr485d/inflammatory

Source: Global Markets Direct

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals